Clearbridge Investments LLC boosted its position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 9.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,541,871 shares of the biopharmaceutical company’s stock after purchasing an additional 307,117 shares during the period. Clearbridge Investments LLC’s holdings in Alexion Pharmaceuticals were worth $423,572,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ALXN. Jennison Associates LLC increased its stake in Alexion Pharmaceuticals by 720.0% in the 3rd quarter. Jennison Associates LLC now owns 5,332,636 shares of the biopharmaceutical company’s stock valued at $748,116,000 after purchasing an additional 4,682,336 shares in the last quarter. Amundi Pioneer Asset Management Inc. increased its stake in Alexion Pharmaceuticals by 1,786.3% in the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 1,454,498 shares of the biopharmaceutical company’s stock valued at $173,944,000 after purchasing an additional 1,377,388 shares in the last quarter. Investec Asset Management LTD purchased a new position in Alexion Pharmaceuticals in the 4th quarter valued at approximately $84,096,000. Alkeon Capital Management LLC purchased a new position in Alexion Pharmaceuticals in the 3rd quarter valued at approximately $70,145,000. Finally, Wells Fargo & Company MN increased its stake in Alexion Pharmaceuticals by 32.7% in the 3rd quarter. Wells Fargo & Company MN now owns 1,558,531 shares of the biopharmaceutical company’s stock valued at $218,647,000 after purchasing an additional 383,713 shares in the last quarter. 93.73% of the stock is owned by hedge funds and other institutional investors.
In related news, EVP Julie O’neill sold 1,625 shares of Alexion Pharmaceuticals stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $119.83, for a total value of $194,723.75. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Heidi L. Wagner sold 655 shares of Alexion Pharmaceuticals stock in a transaction on Monday, February 5th. The shares were sold at an average price of $117.26, for a total value of $76,805.30. Following the completion of the transaction, the senior vice president now owns 32,635 shares in the company, valued at approximately $3,826,780.10. The disclosure for this sale can be found here. In the last ninety days, insiders sold 31,253 shares of company stock valued at $3,656,229. Company insiders own 4.35% of the company’s stock.
Shares of Alexion Pharmaceuticals, Inc. (ALXN) opened at $125.68 on Friday. The company has a market capitalization of $26,603.99, a price-to-earnings ratio of 23.67, a PEG ratio of 1.11 and a beta of 1.13. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.10 and a quick ratio of 2.62. Alexion Pharmaceuticals, Inc. has a 1 year low of $96.18 and a 1 year high of $149.34.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported $1.48 EPS for the quarter, beating the Zacks’ consensus estimate of $1.09 by $0.39. The business had revenue of $909.70 million during the quarter, compared to the consensus estimate of $880.38 million. Alexion Pharmaceuticals had a return on equity of 12.94% and a net margin of 12.48%. The business’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.26 earnings per share. analysts expect that Alexion Pharmaceuticals, Inc. will post 6.12 EPS for the current year.
TRADEMARK VIOLATION WARNING: This piece was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://sportsperspectives.com/2018/03/10/alexion-pharmaceuticals-inc-alxn-shares-bought-by-clearbridge-investments-llc.html.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.